Oncolytics Biotech Inc
Company Profile
Business description
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Contact
322 11th Avenue S.W
Suite 804
CalgaryABT2R 0C5
CANT: +1 403 670-7377
E: mmoore@oncolytics.ca
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
28
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,530.90 | 316.70 | -4.04% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,445.03 | 2,100.90 | -5.18% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,404.62 | 2,445.19 | -10.70% |
| NASDAQ | 15,604.17 | 946.44 | -5.72% |
| Nikkei 225 | 31,744.71 | 2,035.87 | -6.03% |
| NZX 50 Index | 11,833.52 | 391.76 | -3.20% |
| S&P 500 | 5,084.85 | 311.67 | -5.78% |
| S&P/ASX 200 | 7,356.40 | 311.40 | -4.06% |
| SSE Composite Index | 3,130.17 | 211.84 | -6.34% |